DGAP-News: Apricus Biosciences Provides Corporate Update; Files Annual Report for Quarter and Year Ended December 31, 2012
(firmenpresse) - Apricus Biosciences, Inc.
18.03.2013 16:15
---------------------------------------------------------------------------
Company to Host Conference Call/Webcast Today at 1:00 PM ET
SAN DIEGO, 2013-03-18 16:15 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), today provided an update regarding ongoing
corporate activities and announced that its Annual Report on Form 10-K for the
quarter and year ended December 31, 2012 has been filed with the Securities and
Exchange Commission earlier today. As previously announced, the Company will
host its fourth quarter and year end 2012 financial results conference call
today, March 18, 2013 at 1:00 PM ET.
Rusty Ray, Chairman of the Board of Apricus Bio stated: 'The Board continues to
believe that the greatest opportunity for shareholder value creation remains in
the development and commercialization, through strategic partnerships, of the
Company's primary pipeline assets, particularly Vitaros(r) and Femprox(r) for male
and female sexual health. To realize this value, the Company's recent activity
has been centered on ensuring that our resources are properly aligned with our
corporate objectives. We look forward to a number of important milestones
throughout 2013, including the full commercial launch of Vitaros(r) in Canada,
regulatory progress with both Vitaros(r) and Femprox(r) in key territories
throughout the world, and the announcement of additional strategic
partnerships.'
Refocused Strategy on Vitaros(r) and Femprox(r)
-- Announced new corporate strategy focused on Vitaros(r) and Femprox(r). In
January 2013, Apricus Bio announced its corporate goals for 2013, which
includes focusing its corporate strategy and resources on commercializing
its lead product Vitaros(r) (alprostadil 0.3% topical cream), for the
treatment of erectile dysfunction ('ED'), and on further developing through
clinical trials its lead product candidate, Femprox(r) (alprostadil 0.4%
topical cream), for the treatment of female sexual arousal disorder
('FSAD'). Both products utilize Apricus Bio's proprietary NexACT(r)
transdermal delivery platform.
-- Ceasing of funding of French Subsidiaries. In March 2013, Apricus Bio
announced that, as part of its effort to focus resources on its lead
assets, it intends to cease financing its French subsidiaries, Finesco SAS,
Scomedica SAS and NexMed Pharma SAS. The strategic decision to cease
financing its French subsidiaries follows a decrease in the unit's
operating performance resulting from recently enacted pricing policies
affecting drug reimbursement in France and the subsequent, related loss of
certain contract sales agreements.
-- Divestiture of oncology supportive care business. In January 2013, Apricus
Bio announced its plans to seek a buyer for its oncology supportive care
products, which include the rights to Totect(r) (dexrazoxane for injection)
for the treatment for extravasation from intravenous anthracycline
chemotherapy in the U.S. and the Americas, and the U.S. co-promotion rights
to Granisol(r) (granisetron HCl oral solution) for the prevention of nausea
and vomiting associated with certain emetogenic cancer therapies and
radiation.Each of these products is now commercially available and
marketed in the U.S. The planned divestiture will allow Apricus Bio to
better align its resources with its stated corporate objectives.
Key Upcoming Milestones
-- Commercial Launch of Vitaros(r) in Canada through Abbott Laboratories.
Apricus Bio is actively supporting Abbott with their pre-launch efforts,
and continues to expect that a full launch will occur in the first half of
2013.
-- European approval decision for Vitaros(r) in Europe via the Decentralized
Procedure ('DCP'). A decision regarding the approval of Vitaros(r) in Europe
via the DCP with Netherlands as the Reference Member State is expected to
occur in the first half of 2013, followed by national phase approvals in
each of the major markets of Europe. Marketing of Vitaros(r) can then be
initiated in each country by Apricus Bio's commercialization partners. In
Europe, existing ED products currently generate over $1 billion dollar in
sales and Apricus Bio believes a significant portion of the market remains
untreated or undertreated.
-- Obtain feedback from regulatory agencies and initiate next clinical steps
for Femprox(r). In 2013, Apricus Bio expects to announce feedback from its
meetings with Health Canada and the U.S. FDA, as well as its plan for
Femprox(r) clinical development going forward.
-- Secure additional Vitaros(r) partnerships. Vitaros(r) is now partnered in key
markets around the world, including the U.S., Canada, Germany, the United
Kingdom, Italy, the Gulf countries, certain other countries in the Middle
East and Israel. The Company is looking to secure partnerships in the
remaining major global markets.
Conference Call Information
The call can be accessed in the U.S. by dialing 877-407-8031 and outside of the
U.S. by dialing 201-689-8031 and asking the conference operator for the Apricus
Bio Conference Call. The teleconference replay will be available for one week
by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing
201-612-7415. Replay passcode 410469 is required for playback. The conference
call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170645. The webcast replay
will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros(r), for the treatment of
erectile dysfunction, which will be marketed in Canada by Abbott Laboratories,
and Femprox(r), a product candidate, for the treatment of female sexual arousal
disorder, which successfully completed a nearly 400-subject Phase III study in
China.
For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its product
Vitaros(r) for erectile dysfunction , and product candidates Femprox(r) for Female
Sexual Arousal Disorder among others; to have its product and product
candidates receive additional patent protection and be approved by relevant
regulatory authorities in Europe, the United States and Canada and in other
countries; to successfully commercialize such product and product candidates
and other NexACT(r) product candidates and drug delivery technology; to sell its
oncology supportive care business or assets to a third party or parties; to
cease funding to its French subsidiaries and to have such subsidiaries
reorganize or liquidate successfully; and to achieve its other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david(at)argotpartners.com
News Source: NASDAQ OMX
18.03.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
apricus-biosciences-provides-corporate-update
files-annual-report-for-quarter-and-year-ended-december-31
2012
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2013 - 16:15 Uhr
Sprache: Deutsch
News-ID 240389
Anzahl Zeichen: 6287
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Provides Corporate Update; Files Annual Report for Quarter and Year Ended December 31, 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
